First Results for the Solar Neighborhood of the Asiago Red Clump Survey

The Asiago Red Clump Spectroscopic Survey (ARCS) is an ongoing survey that provides atmospheric parameters, distances and space velocities of a well selected sample of Red Clump stars distributed along the celestial equator. We used the ARCS catalog for a preliminary investigation of the Galactic disk in the Solar Neighborhood, in particular we focused on detection and characterization of moving groups.Comment: 2 pages, 1 figure, to appear in the proceedings of "Assembling the Puzzle of the Milky Way", Le Grand Bornand (April 17-22, 2011), C. Reyle, A. Robin, M. Schultheis (eds.

A spectroscopic survey of faint, high-galactic latitude red clump stars. II. The medium resolution sample

Aims. The goal of our survey is to provide accurate and multi-epoch radial velocities, atmospheric parameters (Teff, log g and [M/H]), distances and space velocities of faint Red Clump stars. Methods. We recorded high signal-to-noise (S/N >= 200) spectra of Red Clump stars, over the 4750-5950 Ang range, at a resolving power 5500. The target stars are distributed over the great circle of the celestial equator. Radial velocities were obtained via cross-correlation against IAU radial velocity standards. Atmospheric parameters were derived via chi^2 fit to a synthetic spectral library. A large number of RC stars from other surveys were re-observed to check the consistency of our results. Results. A total of 245 Red Clump stars were observed (60 of them with a second epoch observation separated in time by about three months), and the results are presented in an output catalog. None of them is already present in other surveys of Red Clump stars. In addition to astrometric and photometric support data from external sources, the catalog provides radial velocities (accuracy sigma(RV)=1.3 km/s), atmospheric parameters (sigma(Teff)=88 K, sigma(log g)=0.38 dex and sigma([M/H])=0.17 dex), spectro-photometric distances, (X,Y,Z) galacto-centric positions and (U,V,W) space velocities.Comment: in press in A&

Properties, evolution and morpho-kinematical modelling of the very fast nova V2672 Oph (Nova Oph 2009), a clone of U Sco

V2672 Oph reached maximum brightness V=11.35 on 2009 August 16.5. With observed t2(V)=2.3 and t3(V)=4.2 days decline times, it is one of the fastest known novae, being rivalled only by V1500 Cyg (1975) and V838 Her (1991) among classical novae, and U Sco among the recurrent ones. The line of sight to the nova passes within a few degrees of the Galactic centre. The reddening of V2672 Oph is E(B-V)=1.6 +/-0.1, and its distance ~19 kpc places it on the other side of the Galactic centre at a galacto-centric distance larger than the solar one. The lack of an infrared counterpart for the progenitor excludes the donor star from being a cool giant like in RS Oph or T CrB. With close similarity to U Sco, V2672 Oph displayed a photometric plateau phase, a He/N spectrum classification, extreme expansion velocities and triple peaked emission line profiles during advanced decline. The full width at zero intensity of Halpha was 12,000 km/s at maximum, and declined linearly in time with a slope very similar to that observed in U Sco. We infer a WD mass close to the Chandrasekhar limit and a possible final fate as a SNIa. Morpho-kinematical modelling of the evolution of the Halpha profile suggests that the overall structure of the ejecta is that of a prolate system with polar blobs and an equatorial ring. The density in the prolate system appeared to decline faster than that in the other components. V2672 Oph is seen pole-on, with an inclination of 0+/-6 deg and an expansion velocity of the polar blobs of 4800 +900/-800 km/s. On the basis of its remarkable similarity to U Sco, we suspect this nova may be a recurrent. Given the southern declination, the faintness at maximum, the extremely rapid decline and its close proximity to the Ecliptic, it is quite possible that previous outbursts of V2672 Oph have been missed.Comment: in press in MNRA

Recurrences of ventricular tachycardia after stereotactic arrhythmia radioablation arise outside the treated volume: analysis of the swiss cohort

BACKGROUND AND AIMS Stereotactic arrhythmia radioablation (STAR) has been recently introduced for the management of therapy-refractory ventricular tachycardia (VT). VT recurrences have been reported after STAR but the mechanisms remain largely unknown. We analyzed recurrences in our patients after STAR. METHODS From 09.2017 to 01.2020, 20 patients (68±8y, LVEF 37±15%) suffering from refractory VT were enrolled, 16/20 with a history of at least 1 electrical storm. Before STAR, an invasive electro-anatomical mapping (Carto3) of the VT substrate was performed. A mean dose of 23±2Gy was delivered to the planning target volume (PTV). RESULTS The median ablation volume was 26 ml (range 14-115) and involved the interventricular septum in 75% of patients. During the first 6 months after STAR, VT burden decreased by 92% (median value, from 108 to 10 VT/semester). After a median follow-up of 25 months, 12/20 (60%) developed a recurrence and underwent a redo ablation. VT recurrence was located in proximity of the treated substrate in 9 cases, remote from the PTV in 3 cases and involved a larger substrate over ≥3 LV segments in 2 cases. No recurrences occurred inside the PTV. Voltage measurements showed a significant decrease in both bipolar and unipolar signal amplitude after STAR. CONCLUSION STAR is a new tool available for the treatment of VT, allowing for a significant reduction of VT burden. VT recurrences are common during follow-up, but no recurrences were observed inside the PTV. Local efficacy was supported by a significant decrease in both bipolar and unipolar signal amplitude

Lack of Evidence for the Role of the p.(Ser96Ala) Polymorphism in Histidine-Rich Calcium Binding Protein as a Secondary Hit in Cardiomyopathies

Inherited forms of arrhythmogenic and dilated cardiomyopathy (ACM and DCM) are characterized by variable disease expression and age-related penetrance. Calcium (Ca$^{2+}$) is crucially important for proper cardiac function, and dysregulation of Ca$^{2+}$ homeostasis seems to underly cardiomyopathy etiology. A polymorphism, c.286T>G p.(Ser96Ala), in the gene encoding the histidine-rich Ca$^{2+}$ binding (HRC) protein, relevant for sarcoplasmic reticulum Ca$^{2+}$ cycling, has previously been associated with a marked increased risk of life-threatening arrhythmias among idiopathic DCM patients. Following this finding, we investigated whether p.(Ser96Ala) affects major cardiac disease manifestations in carriers of the phospholamban (PLN) c.40_42delAGA; p.(Arg14del) pathogenic variant (cohort 1); patients diagnosed with, or predisposed to, ACM (cohort 2); and DCM patients (cohort 3). We found that the allele frequency of the p.(Ser96Ala) polymorphism was similar across the general European-American population (control cohort, 40.3-42.2%) and the different cardiomyopathy cohorts (cohorts 1-3, 40.9-43.9%). Furthermore, the p.(Ser96Ala) polymorphism was not associated with life-threatening arrhythmias or heart failure-related events across various patient cohorts. We therefore conclude that there is a lack of evidence supporting the important role of the HRC p.(Ser96Ala) polymorphism as a modifier in cardiomyopathy, refuting previous findings. Further research is required to identify bona fide genomic predictors for the stratification of cardiomyopathy patients and their risk for life-threatening outcomes

A Systematic Analysis of the Clinical Outcome Associated with Multiple Reclassified Desmosomal Gene Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Patients

The presence of multiple pathogenic variants in desmosomal genes (DSC2, DSG2, DSP, JUP, and PKP2) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) has been linked to a severe phenotype. However, the pathogenicity of variants is reclassified frequently, which may result in a changed clinical risk prediction. Here, we present the collection, reclassification, and clinical outcome correlation for the largest series of ARVC patients carrying multiple desmosomal pathogenic variants to date (n = 331). After reclassification, only 29% of patients remained carriers of two (likely) pathogenic variants. They reached the composite endpoint (ventricular arrhythmias, heart failure, and death) significantly earlier than patients with one or no remaining reclassified variant (hazard ratios of 1.9 and 1.8, respectively). Periodic reclassification of variants contributes to more accurate risk stratification and subsequent clinical management strategy. Graphical Abstract

A Systematic Analysis of the Clinical Outcome Associated with Multiple Reclassified Desmosomal Gene Variants in Arrhythmogenic Right Ventricular Cardiomyopathy Patients

The presence of multiple pathogenic variants in desmosomal genes (DSC2, DSG2, DSP, JUP, and PKP2) in patients with arrhythmogenic right ventricular cardiomyopathy (ARVC) has been linked to a severe phenotype. However, the pathogenicity of variants is reclassified frequently, which may result in a changed clinical risk prediction. Here, we present the collection, reclassification, and clinical outcome correlation for the largest series of ARVC patients carrying multiple desmosomal pathogenic variants to date (n = 331). After reclassification, only 29% of patients remained carriers of two (likely) pathogenic variants. They reached the composite endpoint (ventricular arrhythmias, heart failure, and death) significantly earlier than patients with one or no remaining reclassified variant (hazard ratios of 1.9 and 1.8, respectively). Periodic reclassification of variants contributes to more accurate risk stratification and subsequent clinical management strategy. [Figure not available: see fulltext.]

Lack of Evidence for the Role of the p.(Ser96Ala) Polymorphism in Histidine-Rich Calcium Binding Protein as a Secondary Hit in Cardiomyopathies

Inherited forms of arrhythmogenic and dilated cardiomyopathy (ACM and DCM) are characterized by variable disease expression and age-related penetrance. Calcium (Ca 2+) is crucially important for proper cardiac function, and dysregulation of Ca 2+ homeostasis seems to underly cardiomyopathy etiology. A polymorphism, c.286T>G p.(Ser96Ala), in the gene encoding the histidine-rich Ca 2+ binding (HRC) protein, relevant for sarcoplasmic reticulum Ca 2+ cycling, has previously been associated with a marked increased risk of life-threatening arrhythmias among idiopathic DCM patients. Following this finding, we investigated whether p.(Ser96Ala) affects major cardiac disease manifestations in carriers of the phospholamban ( PLN) c.40_42delAGA; p.(Arg14del) pathogenic variant (cohort 1); patients diagnosed with, or predisposed to, ACM (cohort 2); and DCM patients (cohort 3). We found that the allele frequency of the p.(Ser96Ala) polymorphism was similar across the general European-American population (control cohort, 40.3-42.2%) and the different cardiomyopathy cohorts (cohorts 1-3, 40.9-43.9%). Furthermore, the p.(Ser96Ala) polymorphism was not associated with life-threatening arrhythmias or heart failure-related events across various patient cohorts. We therefore conclude that there is a lack of evidence supporting the important role of the HRC p.(Ser96Ala) polymorphism as a modifier in cardiomyopathy, refuting previous findings. Further research is required to identify bona fide genomic predictors for the stratification of cardiomyopathy patients and their risk for life-threatening outcomes

Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe

Background and aims: Implantable cardioverter-defibrillators (ICDs) are critical for preventing sudden cardiac death (SCD) in arrhythmogenic right ventricular cardiomyopathy (ARVC). This study aims to identify cross-continental differences in utilization of primary prevention ICDs and survival free from sustained ventricular arrhythmia (VA) in ARVC. Methods: This was a retrospective analysis of ARVC patients without prior VA enrolled in clinical registries from 11 countries throughout Europe and North America. Patients were classified according to whether they received treatment in North America or Europe and were further stratified by baseline predicted VA risk into low- (25%/5 years) groups. Differences in ICD implantation and survival free from sustained VA events (including appropriate ICD therapy) were assessed. Results: One thousand ninety-eight patients were followed for a median of 5.1 years; 554 (50.5%) received a primary prevention ICD, and 286 (26.0%) experienced a first VA event. After adjusting for baseline risk factors, North Americans were more than three times as likely to receive ICDs {hazard ratio (HR) 3.1 [95% confidence interval (CI) 2.5, 3.8]} but had only mildly increased risk for incident sustained VA [HR 1.4 (95% CI 1.1, 1.8)]. North Americans without ICDs were at higher risk for incident sustained VA [HR 2.1 (95% CI 1.3, 3.4)] than Europeans. Conclusions: North American ARVC patients were substantially more likely than Europeans to receive primary prevention ICDs across all arrhythmic risk strata. A lower rate of ICD implantation in Europe was not associated with a higher rate of VA events in those without ICDs